New awards support research spanning early detection, immunotherapy resistance, predictive biomarkers, and personalized treatment

新奖项支持涵盖早期检测、免疫治疗耐药性、预测性生物标志物以及个性化治疗的研究

WASHINGTON

华盛顿

,

，

Oct. 28, 2026

2026年10月28日

/PRNewswire/ -- LUNGevity Foundation has announced the recipients of six research awards aimed at strengthening the lung cancer research workforce and accelerating progress for people living with lung cancer. The awards reflect LUNGevity's ongoing commitment to advancing innovative research and improving outcomes for patients..

/美通社/ -- LUNGevity基金会宣布六项研究奖的获奖者，这些奖项旨在加强肺癌研究人才队伍，并加速改善肺癌患者的生活。该奖项体现了LUNGevity在推动创新研究和改善患者预后方面的持续承诺。

Over the past two decades, LUNGevity has invested more than $55 million in lung cancer research. The 2026 research awards build on that longstanding commitment by cultivating the next generation of lung cancer researchers and advancing high-impact science.

在过去二十年中，LUNGevity 已在肺癌研究领域投入超过 5,500 万美元。2026 年的研究奖项通过培养下一代肺癌研究人员并推动高影响力的科学研究，延续了这一长期承诺。

'The future of lung cancer research depends on who we empower today. At a time when the oncology workforce is shrinking, strengthening the pipeline of lung cancer researchers has never been more important,' said Upal Basu Roy, PhD, MPH, Executive Director of LUNGevity Research. 'These awards invest in exceptional researchers whose ideas can spark the next generation of breakthroughs.

“肺癌研究的未来取决于我们今天所赋能的对象。在肿瘤学专业人才队伍日益缩小的当下，加强肺癌研究人员的人才储备从未像现在这样重要，”LUNGevity研究基金会执行董事Upal Basu Roy博士（公共卫生硕士）表示。“这些奖项旨在资助杰出的研究人员，他们的思想有望激发下一代突破性进展。”

By supporting their work, we are helping build a stronger future for everyone affected by lung cancer.'.

通过支持他们的工作，我们正在帮助为所有受肺癌影响的人构建一个更美好的未来。

The 2026 Workforce Research Awards were selected by experts in the field to support research in strategic areas where progress is urgently needed:

2026年劳动力研究奖由该领域专家评选产生，旨在支持在亟需取得进展的战略领域开展研究：

Leveraging new tools to solve persistent challenges

利用新工具解决长期存在的挑战

Overcoming resistance to immunotherapy

克服对免疫治疗的耐药性

Predicting which patients will benefit from immunotherapy

预测哪些患者将从免疫治疗中获益

Empowering the immune system to control cancer

增强免疫系统以控制癌症

Improving lung cancer screening and follow-up care in veterans

改善退伍军人的肺癌筛查和随访护理

Expanding personalized adoptive treatment options

拓展个性化适应性治疗选项

LUNGevity is proud to announce the following recipients of the 2026 Translational Research Program Awards.

LUNGevity 自豪地宣布以下 2026 年转化研究计划奖的获得者。

Career Development Awards

职业发展奖

Established in 2012, LUNGevity's Career Development Awards are the Foundation's flagship program for junior investigators who are passionate about pursuing a career in lung cancer.  This sought-after awards program plays an important role in the lung cancer research community by building the future leaders of lung cancer.

LUNGevity 职业开发奖成立于2012年，是该基金会面向热衷于投身肺癌研究领域的新晋研究者设立的旗舰项目。这一备受青睐的奖项计划通过培养肺癌领域的未来领袖，在肺癌研究社群中发挥着重要作用。

Past recipients of this award have developed their own independent research programs, received major grants from the National Institutes of Health and other funders, and even succeeded in getting a new treatment approved by the US Food and Drug Administration.  .

该奖项的往届得主已建立起自己独立的科研项目，获得了来自美国国立卫生研究院及其他资助方的大额资助，甚至成功推动新疗法获得美国食品药品监督管理局的批准。

Researcher:

研究员：

Chris Frangieh, PhD

克里斯·弗兰吉赫，博士

Institution:

机构：

Columbia University Irving Medical Center

哥伦比亚大学欧文医学中心

Project:

项目：

Relief of tonic cGAS-STING signaling in NSCLC

缓解非小细胞肺癌中强直性cGAS-STING信号传导

Total Amount:

总金额：

$300,000

30万美元

Award:

奖项：

Lung Cancer Initiative-LUNGevity Career Development Award

肺癌倡议-LUNGevity职业发展奖

During cell division, cells can acquire chromosomal abnormalities that drive cancer growth. It is well known that, in healthy tissue, the cGAS-STING pathway responds to abnormal chromosomes and triggers an immune response. Dr. Frangieh observed that in cancers that are driven by chromosomal abnormalities, this pathway does not work as it should, allowing tumors to grow.

在细胞分裂过程中，细胞可能获得驱动癌症生长的染色体异常。众所周知，在健康组织中，cGAS-STING通路会对异常染色体作出反应并触发免疫反应。Frangieh博士观察到，在由染色体异常驱动的癌症中，该通路未能正常运作，从而使得肿瘤得以生长。

He and his team have developed a new drug that resets this pathway, and early experiments in lung cancer cells and mice have shown this drug improves immunotherapy efficacy. The team plans to continue this foundational work to develop a novel treatment approach. If successful, this work could help more patients benefit from currently approved immunotherapies..

他和他的团队开发了一种能够重置该通路的新药，在肺癌细胞和小鼠身上进行的早期实验表明，这种药物可以提高免疫疗法的疗效。该团队计划继续开展这项基础性工作，以开发一种新型治疗方案。如果取得成功，这项研究有望帮助更多患者从目前已获批的免疫疗法中受益。

'Unleashing the natural power of the immune system has been the bedrock of immunotherapy in lung cancer,' said Jenni Danai, MPH, Chief Mission Delivery Officer at Lung Cancer Initiative. 'For several years, targeting the cGAS-STING pathway has been a major challenge for researchers. Dr. Frangieh's team is finally making progress in this space.

“释放免疫系统的自然力量一直是肺癌免疫治疗的基石，”肺癌倡议组织首席使命交付官、公共卫生硕士詹妮·达奈表示。“多年来，靶向cGAS-STING通路一直是研究人员面临的一大挑战。弗朗热博士的团队终于在这一领域取得了进展。”

We are excited to see how this work unfolds and the opportunities it provides for new approaches in treating lung cancer.'.

我们很期待看到这项工作的进展，以及它为肺癌治疗新方法带来的机遇。

Researcher:

研究员：

Surbhi Singhal, MD

苏尔比·辛格尔，医学博士

Institution:

机构：

University of California, Davis

加利福尼亚大学戴维斯分校

Project:

项目：

Proteomic determinants of immunotherapy sensitivity in refractory NSCLC

难治性非小细胞肺癌免疫治疗敏感性的蛋白质组学决定因素

Total Amount:

总金额：

$300,000

30万美元

Because some lung cancer patients don't benefit from immunotherapy, doctors often rely on existing tests such as PD-L1 expression or tumor mutation burden to help guide treatment plans.  However, these tests are not always reliable when predicting who will benefit from immunotherapy. Dr. Singhal's project aims to analyze blood samples from 136 patients enrolled in an immunotherapy clinical trial.

由于部分肺癌患者无法从免疫治疗中获益，医生通常依赖PD-L1表达或肿瘤突变负荷等现有检测来指导治疗方案的制定。然而，这些检测在预测哪些患者将从免疫治疗中获益方面并不总是可靠。Singhal博士的项目旨在分析一项免疫治疗临床试验中入组的136名患者的血液样本。

The team will use advanced technology to measure approximately 7,000 proteins in each sample to identify patterns that separate responders from non-responders. Using these protein patterns, the team aims to develop a blood test that helps doctors reliably identify which patients will benefit from specific drugs, enabling more personalized treatment plans..

该团队将利用先进技术测量每个样本中约7,000种蛋白质，以识别区分应答者与非应答者的模式。基于这些蛋白质模式，该团队旨在开发一种血液检测，帮助医生可靠地识别哪些患者将从特定药物中受益，从而制定更加个性化的治疗方案。

Researcher:

研究员：

No Joon Song, PhD

宋俊博士

Institution:

机构：

The Ohio State University Comprehensive Cancer Center

俄亥俄州立大学综合癌症中心

Project:

项目：

NK cell-macrophage crosstalk remodels macrophage states in lung cancer

NK细胞与巨噬细胞的交互重塑肺癌中巨噬细胞的状态

Total Amount:

总金额：

$300,000

30万美元

Immunotherapy has improved outcomes for patients with lung cancer by removing the brakes of the immune system. Yet lasting responses to immunotherapy are uncommon, suggesting that tumors may develop other ways to stop the immune system. Dr. Song's previous work identified natural killer (NK) cells that limit productive CD8 T-cell responses and contribute to immunotherapy resistance.

免疫疗法通过解除免疫系统的抑制机制，改善了肺癌患者的预后。然而，对免疫疗法的持久反应并不常见，这表明肿瘤可能发展出其他途径来抑制免疫系统。宋博士此前的研究鉴定出一种自然杀伤（NK）细胞，这类细胞会限制有效的CD8+ T细胞反应，并导致免疫治疗耐药。

He has also found these NK cells actively restrain macrophages from targeting tumor cells. This project will use advanced profiling and functional studies in lung cancer models to clarify how macrophages are controlled by NK cells and whether disrupting the NK-macrophage interaction enhances response to immunotherapy.

他还发现，这些NK细胞能够主动抑制巨噬细胞对肿瘤细胞的靶向作用。本项目将在肺癌模型中采用先进的谱系分析和功能研究，以阐明NK细胞如何调控巨噬细胞，并评估破坏NK细胞与巨噬细胞之间的相互作用是否能增强对免疫治疗的反应。

By uncovering this new layer of immune suppression in lung cancer, this work offers an opportunity to develop combination therapies that target both the NK-CD8 T-cell interactions and the NK-macrophage interactions to improve how patients benefit from immunotherapy..

通过揭示肺癌中这一新的免疫抑制层面，本研究为开发联合疗法提供了契机，这些疗法可同时靶向NK细胞与CD8+ T细胞的相互作用以及NK细胞与巨噬细胞的相互作用，从而提升患者从免疫治疗中的获益。

Veterans Affairs Research Scholar Awards

退伍军人事务部研究学者奖

This award program is designed to foster a new generation of researchers interested in having a direct impact on improving outcomes for veterans with lung cancer.

该奖项计划旨在培养新一代研究人员，他们致力于直接改善肺癌退伍军人的治疗结果。

Researcher:

研究员：

Brendan Heiden, MD, MBA, MPHS

布伦丹·海登，医学博士，工商管理硕士，公共卫生硕士

Institution:

机构：

Washington University School of Medicine in St. Louis

圣路易斯华盛顿大学医学院

Project:

项目：

Real-world outcomes of screening-detected NSCLC in a national cohort

全国队列中筛查发现的非小细胞肺癌的真实世界结局

Total Amount:

总金额：

$100,000

10万美元

Veterans in the US face a higher risk of developing lung cancer due to several factors, including increased tobacco exposure. The VA has developed one of the country's largest lung cancer screening programs using annual low-dose CT scans. While it is known that screening saves lives, it is not known what happens to patients in the VA once their cancer is found by screening.

由于包括烟草暴露增加在内的多种因素，美国退伍军人面临更高的肺癌发病风险。美国退伍军人事务部（VA）已建立起全国规模最大的肺癌筛查项目之一，采用年度低剂量CT扫描进行筛查。尽管已知筛查能够挽救生命，但对于在VA系统中接受筛查并确诊癌症的患者随后的情况，目前尚不清楚。

In this project, Dr. Heiden will study the VA records of more than 100,000 veterans diagnosed with lung cancer over the past ten years, comparing those who had their lung cancer discovered via screening to those whose lung cancer was found in other ways, to see if there are differences in their stage at diagnosis, treatments received, and long-term survival.

在本项目中，海登博士将研究过去十年中超过10万名被诊断为肺癌的退伍军人的美国退伍军人事务部（VA）病历记录，比较通过筛查发现肺癌的患者与通过其他方式发现肺癌的患者，以观察他们在诊断分期、接受的治疗以及长期生存率方面是否存在差异。

These findings will help the VA improve its screening program, reduce gaps in who gets screened, and improve care for veterans. Results from this study may also help shape lung cancer screening in non-VA hospitals across the country..

这些发现将有助于美国退伍军人事务部（VA）改进其筛查计划，减少筛查覆盖方面的差距，并改善对退伍军人的医疗服务。本研究的结果还可能有助于塑造全国非VA医院的肺癌筛查实践。

Health Equity and Inclusiveness Research Fellow Award

健康公平与包容性研究学者奖

This award program is designed to support researchers interested in conducting lung cancer research that bridges health disparities by engaging underserved or overlooked communities.

该奖项计划旨在支持致力于开展肺癌研究的研究人员，通过动员服务不足或被忽视的社区，弥合健康差异。

Researcher:

研究员：

Tatiana Delgado Cruz, MD

塔蒂亚娜·德尔加多·克鲁兹，医学博士

Institution:

机构：

Weill Cornell Medicine

威尔康奈尔医学院

Project:

项目：

Utilizing the tumor-draining lymph node as a third source of adoptive cell therapy

利用肿瘤引流淋巴结作为过继性细胞疗法的第三来源

Total Amount:

总金额：

$100,000

10万美元

Adoptive cell therapy (ACT) is a form of immunotherapy that uses a patient's own T cells to target and destroy cancer cells. Currently, there are two main sources for ACT cells: 1) white blood cells called tumor-infiltrating lymphocytes (TILs) that are taken directly from tumors for expansion and reinfusion, and 2) peripheral blood T cells that are collected and genetically modified to kill tumor cells.

过继性细胞疗法（ACT）是一种免疫疗法，利用患者自身的T细胞来靶向并摧毁癌细胞。目前，ACT细胞主要有两个来源：1）直接从肿瘤中获取并称为肿瘤浸润淋巴细胞（TILs）的白细胞，经扩增后回输至患者体内；2）采集外周血T细胞，并对其进行基因改造以杀伤肿瘤细胞。

In this project, Dr. Delgado Cruz aims to produce a more reliable source of T cells for ACT by developing tumor-draining lymph nodes with increased antitumor activity. If successful, this work will open the door to a new adoptive cell therapy approach and a more powerful, personalized treatment option for lung cancer..

在本项目中，德尔加多·克鲁兹博士旨在通过开发具有增强抗肿瘤活性的肿瘤引流淋巴结，为过继细胞疗法（ACT）提供更可靠的T细胞来源。如果成功，这项工作将为一种新的过继细胞疗法途径以及更强大、个性化的肺癌治疗选择打开大门。

Researcher:

研究员：

Nehemias Guevara Rodriguez, MD

内赫米亚斯·格瓦拉·罗德里格斯，医学博士

Institution:

机构：

Saint Louis University

圣路易斯大学

Project:

项目：

Quantifying radiographic response in veterans receiving immunotherapy

量化接受免疫治疗的退伍军人的影像学反应

Total Amount:

总金额：

$30,000

30,000美元

Immune checkpoint inhibitors have improved outcomes for many patients with advanced non-small cell lung cancer (NSCLC). However, despite biomarkers such as PD-L1 expression and tumor mutational burden, it is still difficult to predict which patients with stage IV NSCLC will benefit from immunotherapy, and for how long.

免疫检查点抑制剂已改善了许多晚期非小细胞肺癌（NSCLC）患者的预后。然而，尽管存在PD-L1表达和肿瘤突变负荷等生物标志物，仍难以预测哪些IV期NSCLC患者将从免疫治疗中获益，以及获益持续时间有多长。

In this study, Dr. Guevara Rodriguez will utilize existing genomic and clinical databases from the VA to identify better biomarkers for treating advanced NSCLC in the veteran population..

在本研究中，Guevara Rodriguez 博士将利用美国退伍军人事务部（VA）现有的基因组和临床数据库，为退伍军人群体中晚期非小细胞肺癌（NSCLC）的治疗识别更优的生物标志物。

Through these awards, LUNGevity is building a pipeline of lung cancer experts who will drive innovation and discovery to bring us a future where no one dies from the disease.

通过这些奖项，LUNGevity 正在构建一支肺癌专家队伍，他们将推动创新与发现，为我们带来一个无人因肺癌而逝的未来。

About Lung Cancer Initiative

关于肺癌倡议

Lung Cancer Initiative is a leading nonprofit organization supporting lung cancer research and education and connecting patients, survivors and their loved ones with the medical and research community. LCI's mission is to advance survivorship and provide support through research, education, and access programs.

肺癌倡议组织是一家领先的非营利机构，致力于支持肺癌研究与教育，并将患者、幸存者及其亲友与医疗及科研社区紧密联系起来。该组织的使命是通过研究、教育和可及性项目，推动幸存者生存质量的提升并提供支持。

The organization has funded nearly $4 million in lung cancer research and assisted thousands of patients in accessing treatment and support services following a lung cancer diagnosis. For more information about Lung Cancer Initiative, please visit .

该组织已为肺癌研究提供近400万美元的资金支持，并帮助数千名患者在确诊肺癌后获得治疗和支持服务。欲了解更多关于“肺癌倡议”的信息，请访问。

www.lungcancerinitiative.org

www.lungcancerinitiative.org

.

。

About LUNGevity Foundation

关于 LUNGevity 基金会

LUNGevity Foundation is transforming what it means to be diagnosed and live with lung cancer. While many organizations focus on one aspect of lung cancer, LUNGevity works across research, advocacy, and patient support, because lasting progress requires connecting all three.

LUNGevity基金会正在重塑肺癌诊断与患者生活的意义。当许多组织仅专注于肺癌的某一个方面时，LUNGevity则在研究、倡导和患者支持三大领域协同推进，因为持久的进步有赖于将这三者紧密联结。

As the largest nonprofit funder of lung cancer research in the United States, LUNGevity drives progress in early detection, more effective treatments, and the next generation of researchers. We empower people diagnosed with lung cancer and their caregivers with scientifically vetted information, resources, and community and advocate for policies that improve access to screening, biomarker testing, treatment, and high-quality care for all..

作为美国肺癌研究最大的非营利资助方，LUNGevity 推动早期检测、更有效治疗方案以及下一代研究人员的发展进程。我们为肺癌患者及其照护者提供经科学审核的信息、资源和社区支持，并倡导改善所有人获得筛查、生物标志物检测、治疗和高质量护理机会的政策。

By connecting scientific discovery, patient experience, and advocacy, we help ensure research reflects what patients need, breakthroughs reach the people who can benefit from them, and patient voices help drive meaningful change.

通过连接科学发现、患者体验和倡导工作，我们帮助确保研究反映患者的需求，突破性成果惠及能够从中受益的人群，并且让患者的声音推动有意义的变革。

Our vision is a world where no one dies of lung cancer.

我们的愿景是建立一个无人死于肺癌的世界。

Please visit

请访问

www.LUNGevity.org

www.LUNGevity.org

to learn more.

了解更多。

About Lung Cancer in the US

关于美国的肺癌

About 1 in 19 Americans will be diagnosed with lung cancer in their lifetime.

大约每19名美国人中就有1人在其一生中会被诊断出患有肺癌。

More than 229,000 people in the US will be diagnosed with lung cancer this year, with a new diagnosis every 2.3 minutes.

今年美国将有超过22.9万人被诊断为肺癌，平均每2.3分钟就有一例新确诊。

It is estimated that close to 65% of all new lung cancer diagnoses are among people with no tobacco exposure or only past tobacco exposure.

据估计，在所有新确诊的肺癌病例中，近65%的患者从未接触过烟草或仅有既往烟草接触史。

More lives are lost to lung cancer than to the next two deadliest cancers (colorectal and pancreatic) combined.

死于肺癌的人数比死于接下来两种最致命癌症（结直肠癌和胰腺癌）的总人数还要多。

Only 29.5% of all people diagnosed with lung cancer will survive 5 years or more, but if it's caught before it spreads, the chance of 5-year survival improves to 65%.

在所有被诊断为肺癌的患者中，只有29.5%的人能存活5年或更长时间，但如果在癌症扩散之前被发现，5年生存率将提高到65%。

SOURCE LUNGevity Foundation

来源：Lungevity 基金会